Clinical Trial Update: Evaluation of The Performance of Retinow AI Software

View source ↗

Summary

A clinical trial evaluating the performance of Retinow AI software has completed. The study covered diabetic retinopathy, glaucoma, and macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Diabetic Retinopathy
• Glaucoma

Snippet

Sponsor: Retinow Health Technologies and R&D Industry Joint Stock Company | Conditions: Diabetic Retinopathy, Glaucoma | Status: COMPLETED